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Abstract 2 
Lassa fever (LF), a rodent-borne viral haemorrhagic fever, is gaining recognition as an 3 
important endemic disease with severe impacts on some of West Africa’s poorest 4 
communities. Despite growing attention from global health institutions, our knowledge of LF 5 
ecology, epidemiology and distribution is limited. This is a barrier to both short-term disease 6 
forecasting and prevention, and long-term prediction of how future environmental changes in 7 
West Africa may affect Lassa virus (LASV) transmission dynamics between rodents and 8 
people. Here, we synthesize current knowledge of LF ecology and epidemiology to show that 9 
extrapolations from past research have produced an incomplete picture of the disease’s true 10 
incidence and distribution, with negative consequences for policy planning, medical 11 
treatment and management interventions. Although the recent increase in LF case reports is 12 
likely an artefact of improved diagnostics and surveillance, recent studies indicate that socio-13 
ecological changes in West Africa may drive increases in LF burden this century. Future 14 
research to understand the cryptic nature of this disease should focus on geographical 15 
distribution and disease burden, with the aim of improving the integration of LF into public 16 
policy and disease control strategies. 17 
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Lassa fever is an acute and occasionally severe rodent-borne viral haemorrhagic fever, with 25 
cases in humans geographically constrained to sub-Saharan West Africa. Discovered in 1969, 26 
Lassa fever (LF) is endemic to much of rural Nigeria and the countries of the Mano River 27 
Union (Sierra Leone, Guinea and Liberia; MRU) [1]. International interest in Lassa virus 28 
(LASV) has often focused on global health security, since its long incubation period (usually 29 
7-10 days) makes it one of the most commonly exported viral haemorrhagic fevers (VHFs) to 30 
countries outside its endemic range [2]. As a result, LASV is now classified as a Select Agent 31 
by the US Federal Select Agent Program, requiring Biosafety Level-4 conditions for 32 
laboratory study [3]. In contrast, its contribution to the burden of disease in West Africa has 33 
historically been under-appreciated, despite suggestions that it causes considerable annual 34 
morbidity and mortality in some of Africa's poorest communities [1,4]. Awareness of LF as a 35 
public health issue is increasing, especially following the 2013-16 Ebola virus disease (EVD) 36 
epidemic in the MRU, which has galvanized national and international agencies’ attempts to 37 
improve the prediction of and response to disease outbreaks in West Africa. In 2015, the 38 
World Health Organisation listed LF among priority diseases requiring urgent research and 39 
development attention  [5]. In response, LASV was made a priority for vaccine development 40 
funding by the multi-agency Coalition for Epidemic Preparedness Innovations (CEPI), 41 
alongside several other emerging viruses [6]. 42 
 43 
Despite growing interest in LF, our knowledge of its ecology, epidemiology and distribution 44 
in West Africa is limited. For decades, disease surveillance has piggy-backed on biomedical 45 
research projects based in districts where LF is already recognized as a problem. However, 46 
previous seroprevalence studies have suggested high numbers of undiagnosed infections in 47 
non-endemic areas [7–9] and, in recent years, official incidence reports have seen a 48 
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substantial increase in the number and geographical extent of cases, which suggests that the 49 
true incidence and spatial distribution of the disease may be underestimated (Figure 1). This 50 
is a barrier to effective interventions and policy, such as the targeting of future vaccines 51 
towards communities at greatest risk, prioritization in health planning and assessments of 52 
global health security. In this review, we therefore synthesize current knowledge of the 53 
ecology and epidemiology of LF to address several questions with relevance for disease 54 
management. Firstly, what are the key knowledge gaps and research priorities with 55 
implications for LF control and prevention? Secondly, what is the current understanding of 56 
the distribution of LASV in West Africa, and what are the reasons for the recent geographical 57 
expansion in LF case reports? Thirdly, how might projected socio-ecological changes impact 58 
the incidence and distribution of LF in the coming decades? Much of West Africa is 59 
experiencing rapid demographic and environmental shifts that may profoundly affect the 60 
transmission dynamics of many important zoonotic diseases [10,11]. Within LF-endemic 61 
countries these changes are occurring in societal contexts of high levels of poverty, recent 62 
civil conflict, and poor access to healthcare, which increase the complexity of prevention and 63 
management of LF and other diseases such as malaria, cholera, yellow fever and EVD 64 
[12,13]. There is thus a clear need for better integrated knowledge of the drivers of cross-65 
species LASV transmission, to facilitate disease forecasting and inform interventions that will 66 
reduce infection risk in affected communities [10,14]. 67 
 68 
Disease and diagnosis 69 
 70 
In humans LASV causes a wide spectrum of disease manifestations, ranging from 71 
asymptomatic infections to acute and severe disease. Onset of acute LF is gradual and 72 
nonspecific, often beginning with intermittent fever and malaise followed by myalgia, sore 73 
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throat, facial oedema and severe headache [15,16]. Recovery begins eight to ten days after 74 
onset, while fatal cases progress to shock, organ failure and death, sometimes with 75 
haemorrhagic manifestations (see [17] for a recent review of the pathogenesis of LF). 76 
However, haemorrhagic signs are often absent, and less common in LF compared to New 77 
World arenaviral fevers [15,16,18]. Pregnancy is generally recognized as a risk factor 78 
associated with increased LF-related mortality [19,20]. Permanent or temporary sensorineural 79 
hearing loss is a common sequela, affecting up to an estimated 25% of all convalescent LF 80 
patients [21]. Most LASV infections are mild or subclinical; sampled human populations 81 
with high LASV seroprevalence and seroconversion rates often report much lower incidence 82 
of LF-like febrile disease, suggesting regular viral exposure but relatively few acute cases 83 
[4,7,15,22,23]. The reasons for this variation in pathogenesis are unknown, although 84 
proposed mechanisms include variation in LASV strain virulence [7,24,25], and differences 85 
in genetic susceptibility to LASV infection between human populations [26]. There is 86 
currently no available LF vaccine, and although several candidate vaccines have been 87 
developed to various stages, no human trials have occurred to date [27,28]. However, this 88 
may change in the near future with the recent prioritisation of LASV by CEPI alongside 89 
ongoing research into LF vaccine design [6,29] 90 
 91 
One major barrier to LF research is the difficulty of diagnosis based on clinical signs and 92 
symptoms alone. Early-stage LF presents similarly to other febrile illnesses (e.g. malaria, 93 
typhoid fever, EVD) [15], and LF is often only suspected after development of haemorrhagic 94 
symptoms in the late stages of disease. Milder cases in the community therefore often go 95 
unrecognized and unreported, with only severely ill people referred for LF testing and 96 
treatment [20]. Most health facilities in West Africa have limited access to laboratory testing 97 
to confirm diagnosis of LF [30], which requires either viral detection by RT-PCR, antibody 98 
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or antigen detection by enzyme-linked immunosorbent assay (ELISA), or viral isolation 99 
(recently reviewed in [31]). The lack of easily-accessible diagnostics for LF has implications 100 
for medical treatment since it may delay the commencement of ribavirin therapy, which is 101 
most effective when administered during early stage disease [20,32]. Lack of diagnostics has 102 
also resulted in under-reporting of LF cases, and a geographical bias in LF detections nearby 103 
to established laboratories, such as the dedicated Lassa Fever Ward at Kenema General 104 
Hospital, Sierra Leone (KGH) and the Institute of Lassa Fever Research and Control at Irrua 105 
Specialist Teaching Hospital, Nigeria [33–35]. 106 
 107 
The consequence of under-reporting has been to confound understanding of the incidence, 108 
geographical distribution and mortality of LF. Annual case estimates are often cited as 109 
100,000-300,000 LASV infections and around 5000 deaths per year across West Africa, but 110 
these are extrapolations from one longitudinal study in Sierra Leone in the 1980s [4], and 111 
have not been subsequently adjusted for population increases or improvements in diagnostic 112 
sensitivity and specificity. Other studies have confirmed that LF is a significant contributor to 113 
infectious disease burden in hyper-endemic areas of Nigeria and the MRU [15,23], but its 114 
incidence across West Africa remains poorly understood. Under-reporting of milder cases 115 
may also be one reason for the marked contrast in reported case fatality rates between 116 
community and clinic, which vary from 2% in the community to over 60% in hospital 117 
settings [15,16,20]. Despite growing interest in LF from a public health perspective, these 118 
knowledge gaps have to date precluded formal quantitative assessments of the total burden of 119 
LF and LF-associated sequelae. With diagnostic tests improving, longitudinal studies are 120 
needed throughout tropical West Africa to characterise the spectrum of infection severity and 121 
assess the disease's true incidence and burden. This would be an important step towards 122 
shifting the global health narrative often associated with LF away from biosecurity [10], and 123 
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towards a more nuanced understanding of LF as a neglected endemic disease and significant 124 
public health concern. 125 
 126 
Ecology, epidemiology and transmission of Lassa virus 127 
 128 
Reservoir host ecology and epidemiology 129 
 130 
Lassa virus is a single-stranded RNA virus (Family: Arenaviridae) which, similarly to most 131 
other arenaviruses, is primarily associated with a single rodent reservoir host species. The 132 
LASV reservoir host, the Natal multimammate rat Mastomys natalensis [36], is one of the 133 
most widespread rodent species in sub-Saharan Africa [37] and its presence is a major spatial 134 
predictor of human LF risk [38]. In West Africa, M. natalensis is abundant in rural human 135 
homes, surrounding agricultural fields and gardens, occurring at much lower densities in 136 
forested and urban areas [39–43]. The high likelihood of human-host contact results in 137 
regular spillover and endemic disease in rural areas where LASV is maintained in the rodent 138 
population (Figure 2), which is in contrast with many VHFs that occur in sporadic outbreaks 139 
such as EVD and yellow fever. LF is primarily a rural disease, with very few cases 140 
originating from large urban areas [1]. This may be due to the low abundance of M. 141 
natalensis in heavily built-up environments, possibly because of competitive interactions 142 
with invasive rodent communities (especially Rattus rattus and Mus musculus) and increased 143 
use of concrete for houses and streets in urban areas [42,44]. 144 
 145 
There has been extensive research into Mastomys natalensis population ecology, motivated 146 
by the species' status as both major agricultural pest and reservoir of several important human 147 
diseases, including plague (Yersinia pestis), bartonellosis (Bartonella spp.), leishmaniasis 148 
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(Leishmania spp.) and leptospirosis (Leptospira spp.) [45–47]. However, the ecology and 149 
epidemiology of LASV in M. natalensis is complex and not well understood. Most evidence 150 
comes from long-term research projects in Guinea (West Africa), where LASV is endemic, 151 
and Tanzania (East Africa), where M. natalensis populations host other arenaviruses 152 
including Morogoro virus (MORV) and Gairo virus (GAIV) [40,43,48,49]. The latter two 153 
viruses are closely related to LASV but non-pathogenic to humans, and as such are 154 
potentially useful model systems for understanding arenavirus ecology in this species. In both 155 
regions, M. natalensis shows seasonal population dynamics that are linked to trends in 156 
rainfall. Although capable of breeding all year round, the rainy season is associated with 157 
higher fecundity and peaks in recruitment, which may be linked to crop maturation and 158 
increased food availability, and population crashes often occur in the dry season [39,41]. 159 
These dynamics appear to be less strongly pronounced in studies from Guinea, where M. 160 
natalensis is found at highest densities inside houses and in proximal cultivated areas [40] 161 
than in many trapping studies conducted in Tanzanian agricultural and mosaic landscapes 162 
[e.g. 39,50]. Evidence from both laboratory and field studies suggests that LASV, MORV 163 
and GAIV are minimally pathogenic in M. natalensis, consistent with long-term coevolution 164 
for persistence in strongly fluctuating reservoir host populations [51,52].  165 
 166 
The mechanisms of LASV transmission in wild rodent populations are unclear. Several 167 
studies have proposed an important role of LASV transmission from mothers to offspring 168 
(vertical transmission). For example, Mastomys neonates experimentally infected with LASV 169 
or MORV develop chronic infections with persistent viral shedding [51,53]. However, 170 
although laboratory studies can shed light on the biological plausibility of transmission 171 
mechanisms, their capacity to adequately represent predominant and critical modes of 172 
transmission under natural conditions may be more limited [54]. Field research suggests that 173 
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the main mode of LASV and MORV transmission in wild rodents is between individuals of 174 
the same generation (horizontal transmission), leading to short duration infection with 175 
transient viral shedding [41]. Evidence for horizontal transmission includes a positive 176 
relationship between age and viral antigen prevalence (an indicator of active infection) in 177 
juvenile rats [41], and also positive correlations between rodent age and antibody 178 
seroprevalence, indicating increasing likelihood of exposure with age [42,52,55]. Horizontal 179 
transmission routes are poorly understood, but there is indirect evidence for a role of rodent 180 
behavior. For example, seroprevalence data from Tanzania suggest that MORV transmission 181 
may be density-independent [43] and that sexual behavior may be involved in GAIV 182 
transmission [52]. 183 
 184 
Overall, the current evidence suggests that most transmission in wild rodents is horizontal, 185 
but that a smaller amount of vertical transmission (leading to chronic infections) may 186 
contribute to viral persistence in the population [41,43,55]. The highest proportion of live 187 
LASV and MORV infections (indicated by presence of viral RNA or antigen) is often found 188 
in young animals [41,43], suggesting that the rapid influx of susceptible juveniles during 189 
rainy season peaks in recruitment may be a driver of documented seasonal fluctuations in 190 
rodent LASV seroprevalence [40,42]. Understanding these dynamics is not merely of 191 
ecological interest, since trends in rodent LASV prevalence may drive spatiotemporal 192 
variation in the force of zoonotic infection to humans. Uncertainty regarding LASV 193 
transmission in rodent populations is a key knowledge gap that could inform, for example, 194 
optimal rodent control and LF prevention regimes in endemic areas. 195 
 196 
One factor that may limit the usefulness of MORV and GAIV as ecological models for 197 
LASV is their seemingly low host plasticity. To date both viruses have only been found in M. 198 
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natalensis and are non-pathogenic to humans [56]. In contrast, evidence of LASV infections 199 
is regularly detected in other rodents, including R. rattus and M. musculus, although these 200 
appear to be transient hosts [42]. The picture of LASV ecology has also been complicated by 201 
the recent identification of two other putative LASV reservoir hosts, Hylomyscus pamfi and 202 
Mastomys erythroleucus [57]. LASV-seropositive M. erythroleucus have been trapped in 203 
regions where M. natalensis is absent but seropositivity is documented in humans, suggesting 204 
that this species may be involved in zoonotic transmission [57]. This highlights the need for 205 
further work to fully understand the spectrum of reservoir and transient hosts, and identify 206 
where other species than M. natalensis may be involved in LASV persistence in the reservoir 207 
community. 208 
 209 
Zoonotic transmission dynamics and human epidemiology 210 
 211 
The routes of LASV zoonotic spillover are poorly understood. Similarly to other arenaviruses 212 
and hantaviruses, human LASV infections are thought to mostly occur via contact with 213 
infected rodent excreta, such as through contaminated food and inhalation of aerosols from 214 
dried urine or droppings (Figure 2) [4,58]. Most contact probably occurs in houses, gardens 215 
and fields, where rodent densities are highest [59–61]. However, the routes of LASV 216 
infection have not been definitively established; for example, to date there has been no testing 217 
of environmental samples to identify highest risk rodent-human interfaces (e.g. houses, 218 
fields) and to understand the conditions that facilitate persistence of LASV in the external 219 
environment. Hunting and butchering of rodents has been shown to be associated with 220 
increased risk of LF-like febrile disease [58], although the evidence remains inconclusive, 221 
with other studies finding no significant relationship between rodent hunting and butchering 222 
and LASV IgG prevalence [22]. The relative risk of infection through butchering may also be 223 
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affected by preferences for eating particular rodent species. For example, in areas of Sierra 224 
Leone, rodents captured from fields, where M. natalensis often occurs at lower densities, are 225 
more likely to be butchered and eaten than rodents captured in villages [62]. It is also 226 
unknown what modes of contact, such as direct contact with rodent blood or inhalation of 227 
urine-contaminated dust particles, are associated with higher risk of virus transmission. 228 
Several social factors are also associated with LF risk, including housing quality, evidence of 229 
rodent burrows in houses, and high human densities in homes [63]. 230 
 231 
Like many endemic tropical diseases, LASV spillover dynamics emerge from complex 232 
interactions between multiple human and environmental factors [59]. In rodents such factors 233 
may include seasonal population and viral transmission dynamics [39,41,42] and behaviour 234 
such as consumption of food in people’s homes[40], and in people may include variation in 235 
rodent consumption [62], land use practices [59,64] and age and gender-related exposure risk 236 
[20,59]. This complexity presents challenges for risk forecasting and planning interventions, 237 
since local social-ecological system dynamics may vary across tropical West Africa. There is 238 
strong evidence of seasonal patterns in infection risk, with hospitalized cases peaking during 239 
the dry season [4,15,20,65], but the drivers of these peaks remain poorly understood. Rainfall 240 
is associated with LF risk [66], which may relate to the link between rainfall and M. 241 
natalensis recruitment and population density [39]. In Sierra Leone there is evidence that dry 242 
season land use practices, such as soil perturbation, burning of fields to prepare for planting, 243 
wetland cultivation and rodent pest management, may bring people into closer contact with 244 
rodents [59,64,65]. Human-reservoir contact rates may also vary due to seasonal movement 245 
of rodents into homes and gardens to seek stored food, but the evidence of seasonal 246 
differences in M. natalensis abundance between villages and fields is inconclusive [40,42]. 247 
Seasonal and spatial variation in human activities such as rodent butchering and farming may 248 
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also drive peaks in zoonotic transmission [14,62], but this needs more investigation. There is 249 
an urgent need for further combined ecological and social science research into the drivers of 250 
LASV spillover dynamics (e.g. [14,59,65]) throughout West Africa. This is required to both 251 
improve early-warning LF forecasts, for example by identifying key environmental drivers 252 
(e.g. high rainfall and other climatic fluctuations) that are strongly predictive of future 253 
outbreaks, and to identify high-risk human-rodent interactions that are suitable for targeted 254 
interventions to reduce risk. 255 
 256 
Human-to-human LASV transmission can occur via contact with infected bodily fluids, and 257 
nosocomial transmission has been documented [67,68]. However, recent research supports 258 
the long-held hypothesis that a majority of LF cases are acquired from rodents rather than 259 
people. Epidemiological modelling of LF admissions data from KGH showed that around 260 
20% of hospitalized cases were attributable to human-to-human transmission [69], although 261 
genomic evidence from LASV isolates from hospital patients in Sierra Leone and Nigeria 262 
suggests that human-to-human infections are much rarer [70]. This discrepancy may be 263 
related to the apparent role of super-spreaders in driving many of the human-to-human cases 264 
in the KGH data [69]. Teasing apart human- from rodent-acquired infections in affected 265 
communities is difficult, since in both cases transmission occurs in similar settings (e.g. in the 266 
home, on farms). Better knowledge of this gap, such as the factors that increase transmission 267 
risk between people and the drivers of super-spreading events, could improve efforts to 268 
manage LF in community settings. Interestingly, the long persistence of viruria (3-9 weeks) 269 
during the post-recovery phase of human disease also suggests a possible mechanism by 270 
which human-to-rodent transmission could contribute to community maintenance of LASV 271 
[69], although this has not been investigated. 272 
 273 
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Distribution and phylogeography of Lassa virus 274 
 275 
The geographical distribution of Lassa fever is unusual in that it appears to be non-276 
contiguous, with confirmed LF cases until recently confined almost entirely to areas of 277 
Nigeria, Sierra Leone, Guinea and Liberia (Figure 1). The countries in-between have 278 
historically been considered non-endemic for LF, despite serological evidence of LASV or a 279 
cross-reactive arenavirus in rodents and/or humans in Mali, Cote d'Ivoire, Ghana and Burkina 280 
Faso (Figure 1) [1]. However, evidence is growing to support a substantially expanded 281 
endemic range of LASV, with human LF outbreaks recently confirmed in southern Mali, 282 
Togo, Burkina Faso, Ghana, Benin and Cote d'Ivoire [24,71–73], and serosurveys showing 283 
LASV circulation at up to 50% prevalence in M. natalensis populations in southern Mali 284 
[74].  285 
 286 
Three distinct LASV lineages currently circulate in Nigeria (lineages I-III) and another 287 
(lineage IV) in the MRU area [70] (Figure 3a), and a recently proposed lineage V is formed 288 
of isolates from Mali and Cote d'Ivoire [73]. Current phylogeographic evidence suggests that 289 
this complex of extant LASV strains originated in Nigeria approximately 1060 years ago and 290 
spread to neighbouring countries between 300 and 500 years ago, before arriving last in the 291 
Mano River Union (MRU) area around 150 years ago [25,70] (Figure 3b). Another putative 292 
Nigerian strain, related to lineages I, II and III, was recently isolated from proposed reservoir 293 
host species H. pamfi, providing further evidence that LASV appears to be more widespread 294 
and ecologically complex than previously thought [57]. 295 
 296 
Knowledge of the true spatial distribution of LASV in rodents across West Africa is 297 
confounded by the same problems that impair understanding of LF incidence, i.e. limited 298 
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access to accurate diagnostics and poor surveillance and monitoring. Surveillance for LASV 299 
in rodents has been biased towards known LF-endemic countries, and a lower awareness of 300 
LF outside these regions means that past human outbreaks elsewhere may have often gone 301 
undiagnosed [75]. Several past risk maps produced for LF (seen in [66] and [76]) probably 302 
misrepresent the true LASV distribution, since this geographical reporting bias is often not 303 
accounted for during statistical modelling [75]. This problem is compounded by both poor 304 
access to diagnostic facilities in more remote areas and the potential for detection errors in 305 
serological assays. Multiple arenaviruses have been identified in M. natalensis and other 306 
rodents in West and Central Africa, and although LASV assay specificity has improved in 307 
recent years, cross-reactivity with other closely-related viruses can lead to false positive 308 
detections [55,77,78]. Such uncertainty is likely to apply particularly to older records, for 309 
example an arenavirus identified as LASV was reported in several Central African countries 310 
in the 1980s [1], but the lack of subsequent detections of LASV or LF outside West Africa 311 
suggests these may have been erroneous. False negatives in detection and diagnosis are also 312 
possible because of the high genetic diversity among extant LASV strains. LASV is 313 
unusually diverse across its range (up to 27% nucleotide and 14.8% amino acid divergence in 314 
the nucleoprotein (NP) gene) compared to other VHF agents such as EBOV [25,70,79], 315 
prompting recent proposals that LASV might best be defined as a species complex [57]. 316 
 317 
Other possible reasons for the larger geographical distribution of LASV than of reported 318 
human LF may be variations in either the genetic resistance of human populations or the 319 
pathogenicity of LASV strains. Such mechanisms might be responsible for the apparent lack 320 
of LF in certain regions (such as southern Mali) where substantial rates of human and rodent 321 
seroprevalence have been documented [7]. Recent large genomic studies have provided some 322 
evidence to support this hypothesis. For example, evidence has been found of positive 323 
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selection on genes biologically linked to LASV infection in the Yoruba people of Nigeria, 324 
suggesting some degree of evolved resistance [26]. An extensive study of LASV isolates 325 
from humans and rodents across West Africa reported higher values for viral traits associated 326 
with virulence in isolates from Sierra Leone compared to those from Nigeria, which the 327 
authors suggested could contribute to the higher case fatality rates recorded in Sierra Leone 328 
[70]. The difference in fatality rates could instead be due to socioeconomic (e.g. poverty, 329 
nutritional status) or clinical factors [70], but such variation in pathogenicity is plausible 330 
given the high genetic diversity of the LASV complex. 331 
 332 
Perhaps more difficult to explain, but relevant to disease prevention, are heterogeneities in 333 
LASV distribution in rodent populations at both large and local geographical scales. In LF-334 
endemic areas there is large variation in LASV infection prevalence in M. natalensis between 335 
neighbouring villages, and sometimes even between houses within a village [42,55]. 336 
Population genetic studies suggest that this may be due to the species' limited dispersal range 337 
[56,80,81], but there is also evidence of regular human-mediated movement of LASV and/or 338 
infected rodents over longer distances [49,79,82], suggesting that road transport networks 339 
have the potential to facilitate virus dispersal to LASV-free areas. However, the current 340 
prevalence and genetic diversity of LASV in M. natalensis populations remains unknown for 341 
most of West Africa. Future research is needed to address these data gaps and evaluate 342 
epidemiological connectivity between rodent subpopulations at both local (within-country) 343 
and regional scales, similarly to recent work on fruit bat (Eidolon helvum) hosts of 344 
henipaviruses and Lagos bat virus [83].  345 
 346 
Another key question concerns the geographical limits of the LASV distribution. Despite M. 347 
natalensis occurring throughout sub-Saharan Africa, laboratory-confirmed LF cases have 348 
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only ever been recorded in West Africa (west of the Nigeria-Cameroon border). 349 
Phylogeographic evidence suggests that West African M. natalensis forms a distinct clade 350 
from the rest of the continent, with LASV having apparently evolved in this western clade 351 
[38,84] (Figure 3b). It is unknown whether the limited LASV distribution is due to biological 352 
factors (e.g. host resistance to infection, coinfection dynamics with other arenaviruses) or 353 
geographical barriers to host dispersal (the Sahara Desert to the North and the Cameroonian 354 
highlands to the East). In particular, it is unclear whether variation in LASV reservoir host 355 
competence exists in different African M. natalensis populations, and how this may affect the 356 
distribution of LF. A recent study in Tanzania found strong spatial segregation of MORV and 357 
GAIV infection across an apparently geographically contiguous Natal multimammate rat 358 
population [56]. This segregation appears to be a result of host-virus coevolution, with the 359 
study results showing that MORV and GAIV are each restricted to a separate matrilineal 360 
subclade of M. natalensis. These results suggest that genetic variation in host competence 361 
between different M. natalensis subclades might restrict LASV to western clade animals [56]; 362 
if this were the case, then future range expansions of LASV beyond West Africa would be 363 
unlikely. However, as discussed above, LASV shows much greater host plasticity than 364 
MORV and GAIV, meaning that this remains an open question. Extensive testing of both 365 
human and rodent populations is needed along the eastern boundaries of the known LF 366 
distribution (eastern Nigeria and the border with Cameroon), in order to elucidate the role of 367 
resistance and coinfection on the spatial distribution of the disease. Unpicking these factors 368 
will be key to determining whether projected climate and land use change could drive an 369 
eastward range expansion and emergence of LF elsewhere in Africa, and thereby designing 370 
appropriate preventative measures. 371 
 372 
Forecasting Lassa fever risk and responses to environmental change 373 




Trends in LF during this decade have followed a pattern typical of an emerging pathogen, 375 
with a notable increase in suspected and confirmed LF outbreaks across a growing area of 376 
West Africa (Figure 1) [20,71,72,85]. Sources of case reports have also shifted from mainly 377 
research publications to disease surveillance reports (see supplementary data). Rather than a 378 
phase shift in LASV ecology, this apparent trend of emergence is most likely a function of 379 
increasing surveillance for LF and other VHFs in West Africa under both public health and 380 
biosecurity agendas. For example, the accuracy of LASV diagnostic tools and accessibility of 381 
suitable laboratory facilities across West Africa have improved over the last decade [10,20]. 382 
There is also increasing political will and institutional funding for VHF surveillance in 383 
Africa, with the roll-out of disease surveillance policy frameworks such as the WHO 384 
International Health Regulations (IHR2005) and Integrated Disease Surveillance and 385 
Response (IDSR), and especially following the severity and slow global response to the 386 
2013-2016 EVD epidemic in West Africa [86]. As a result, a fuller picture of the endemic 387 
distribution of LF and LASV has started to emerge.  388 
 389 
Although the current broadening geographical range of reported LF is unlikely to be a true 390 
range expansion, regional environmental changes may impact LF ecology and epidemiology 391 
in several ways (Figure 4). West Africa has experienced profound environmental, 392 
socioeconomic and demographic shifts in recent decades, including population growth, land 393 
use change (including deforestation, mining and commercial agricultural expansion), 394 
bushmeat extraction, urbanization and growing transport connectivity [10,87]. The region is 395 
also forecast to experience strong climate change effects, impacting crop yields alongside 396 
other important ecosystem services [88]. Such anthropogenic processes are thought to be 397 
major drivers of zoonotic and vector-borne disease [89]. Ecological niche modelling has 398 
Understanding the cryptic nature of Lassa fever in West Africa (revised  Pathogens & Global Health) 
 
 17 
identified key environmental variables correlated with LF outbreaks, in particular rainfall, 399 
human population density and rice yields [38,66]. Future climate projections for West Africa 400 
involve warmer temperatures and increased rainfall, which are predicted to increase the 401 
climatic suitability for M. natalensis across much of the region [38]. Most land use forecasts 402 
predict extensive cultivated land expansion, both for subsistence and commercial export 403 
agriculture (e.g. oil palm) [10,90]. This could drive increases in human LASV exposure by 404 
expanding suitable habitat for M. natalensis, facilitating the spread of LASV between 405 
geographically separate rodent populations, or driving shifts in ecological community 406 
composition towards higher densities of generalist small mammals (including Mastomys) in 407 
more intensively managed land (dilution effects) [91,92]. Such land use homogenization has 408 
been hypothesized as a driver of EBOV emergence in West Africa [11]. Alternatively, it has 409 
been proposed that expansion of mechanized commercial agriculture might reduce M. 410 
natalensis populations [93], thereby decreasing LASV exposure, but at the cost of reducing 411 
community access to land for subsistence farming [94]. A useful but challenging future step 412 
with policy relevance would be to evaluate the trade-offs associated with different land use 413 
futures, incorporating zoonotic disease burden alongside other ecosystem services with 414 
poverty, human health and conservation relevance [95].  415 
 416 
The ability to predict the effects of these environmental drivers depends on unpicking how 417 
different anthropogenic processes impact viral transmission. Prospective field-based studies 418 
into the ecology and epidemiology of LASV in human-dominated ecosystems, including 419 
longitudinal monitoring of rodents and humans over months and years, are required to 420 
elucidate the spatial and seasonal dynamics of disease with less detection bias. The 421 
environmental and behavioral routes of rodent-to-human LASV transmission can be 422 
identified through community-based studies. Ecological and epidemiological modelling is 423 
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also required to evaluate the impacts of different drivers on transmission, inform disease 424 
management and enable forecasting. For example, LF was recently used as a case study 425 
system for novel, One Health-informed modelling approaches [14,59]. A recent study 426 
developed a theoretical framework, based on a generalization of Poisson processes, to jointly 427 
model zoonotic spillover and onward human-to-human transmission, in order to evaluate the 428 
effects of biological, ecological and social parameters on transmission outcomes [65]. 429 
Modelling Kenema General Hospital LF data as a case study, their results again suggested 430 
that seasonal variation in infection risk may underpin the observed distribution of 431 
hospitalized cases. Another recent analysis developed a large-scale, spatially-explicit 432 
compartmental model to evaluate the impacts of future climate, land-use and socioeconomic 433 
scenarios on human LASV infections (Figure 4a) [38]. Their results suggested that climate 434 
change and population growth may lead to a doubling of LASV infections by 2070 (Figure 435 
4b). Such studies make many simplifying assumptions, and given the gaps in knowledge of 436 
the present-day LASV ecology and distribution, any resulting predictions involve large 437 
amounts of uncertainty. Nonetheless, the advantage of such process-based frameworks is in 438 
enabling diverse information to be incorporated into model parameters, including both 439 
biological (e.g. host abundance, immunity, infection prevalence) and socio-ecological factors 440 
(e.g. land use practices, rodent consumption, age-related variation in exposure risk, human 441 
movement) [96–98]. This creates the potential to move away from small-scale and correlative 442 
risk mapping towards a predictive system dynamics approach that considers zoonotic disease 443 
dynamics as a function of multiple interacting environmental and social drivers.  444 
 445 
Recent multidisciplinary case studies of LF in Sierra Leone have emphasized that such 446 
integrated knowledge can inform interventions to reduce exposure to the viral reservoir, such 447 
as land management practices, food storage and rodent control [10,59]. LF is potentially a 448 
Understanding the cryptic nature of Lassa fever in West Africa (revised  Pathogens & Global Health) 
 
 19 
good model system for operationalizing and assessing the outcomes of such a One Health-449 
informed approach, since it is tractable to study; its single primary host species and high 450 
prevalence in rodent populations make ongoing monitoring more practically viable than for 451 
most other VHFs. There is potential for insights into LF management to be applied to 452 
ecologically similar rodent-borne viruses such as New World arenaviruses and hantaviruses 453 
[99,100]. However, as a mainly single host system, any insights into LF may be less relevant 454 
to more complex disease systems with multiple reservoir, amplifying host or vector species 455 
which each respond differently to environmental drivers (e.g. yellow fever, EBOV, 456 
chikungunya) [101]. Since LASV is much less transmissible between people than viruses 457 
such as EBOV, it may also be less useful as an epidemiological model for epidemic VHFs, 458 
where single spillover events can lead to extended chains of human-human transmission.  459 
 460 
Summary and outstanding questions 461 
 462 
In this review we have shown that past biases in LF research have produced an incomplete 463 
picture of the disease's true incidence and distribution in West Africa, with consequences for 464 
medical treatment and disease management. We therefore close by emphasizing several 465 
critical knowledge gaps that must be filled to improve LF prevention and forecasting. These 466 
are: (1) Establishing the true spatial and seasonal distribution of LASV in rodent populations 467 
across West Africa, and how these correlate with observed spatiotemporal trends in human 468 
LF infections (both acute and asymptomatic). This will require longitudinal studies of LASV 469 
seroprevalence in people and rodents throughout the predicted geographic range of the virus, 470 
alongside improved disease monitoring of at-risk human populations inside and outside the 471 
known LF-endemic range. (2) Unpicking the mechanisms of zoonotic LASV transmission, 472 
including behaviors and local practices (e.g. housing, land use, rodent consumption) that 473 
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enhance infection risk. (3) Identifying geographical variation and genetic correlates of LASV 474 
strain virulence and human and rodent susceptibility to LASV infection. Are certain virus 475 
lineages more pathogenic than others, and does innate resistance to infection vary across 476 
human and rodent subpopulations in West Africa, and how do these affect understanding of 477 
who is most at risk? (4) Identifying the barriers (biological, geographical and/or ecological) 478 
that limit LASV to M. natalensis populations in West and Central Africa.  479 
 480 
The growing attention on LF by global health institutions, such as its recent prioritization for 481 
vaccine development, is a positive trend, especially given the consistent impacts of the 482 
disease on many districts that were also severely affected by the 2013-16 Ebola epidemic. 483 
Nonetheless, a continued shift in institutional understanding is required towards treating LF 484 
as a high-burden neglected disease rather than an epidemic threat. The situation should be 485 
improved by ongoing improvements in diagnostics and surveillance, which may provide the 486 
data required for a more robust assessment of the true burden of LF on communities in West 487 
Africa. Simultaneously, further unpicking the complex ecological drivers of LASV dynamics 488 
will enable improved forecasting and targeted medical and environmental interventions.  489 
 490 
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Figure captions 845 
 846 
Figure 1: The known distribution and reported history of Lassa fever and Lassa virus in 847 
West Africa. Points on the map represent human LF outbreak reports in West Africa (both 848 
suspected and confirmed) from 1952-2016 with a confirmed geographical locality (n=102) 849 
(colored per time period). Each point represents a separately reported cluster of cases from 850 
either a research publication or surveillance report, which may span multiple years of 851 
surveillance. Grey shading represents sub-national administrative regions with evidence of 852 
LASV or a LASV-like arenavirus in either humans or rodents. Inset shows a bar chart of per-853 
year LF outbreak reports (both with and without a confirmed geographical locality, n=129), 854 
with each denoted by its reported start year. Data and sources are provided in supplementary 855 
data.  856 
 857 
Figure 2: Transmission dynamics of Lassa virus in rodents and humans. The primary 858 
reservoir host, the Natal multimammate rat (Mastomys natalensis, pictured top left), is a 859 
synanthropic species that is widespread throughout rural sub-Saharan West Africa. Other 860 
putative rodent reservoir species have been identified, but there is currently little data on 861 
LASV prevalence within these populations or routes of transmission to people. It is unknown 862 
whether and how often human-to-rodent transmission occurs (photographs © A. Wilkinson). 863 
 864 
Figure 3: Phylogeography of Lassa virus and its reservoir host Mastomys natalensis. (A) 865 
Phylogeny of Lassa virus isolates from humans and rodents, and (B) reconstructed LASV 866 
evolutionary history across West Africa. (C) Cytochrome b phylogenetic tree of M. natalensis 867 
sampled from across the species’ full range of sub-Saharan Africa, and (D) the geographical 868 
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distribution of samples. M. natalensis in West Africa form a separate clade from the rest of 869 
the continent (clade 1, shown in green). LASV appears to only occur in this western clade. 870 
(A-B reproduced from [70], with permission from Elsevier. C-D reproduced from [38], © 871 
2016 The Authors, under CC BY 4.0 license https://creativecommons.org/licenses/by/4.0/). 872 
 873 
Figure 4: Present and predicted future distribution of Lassa fever risk in West Africa, 874 
estimated from environmental-mechanistic models. Colour scales show predicted annual 875 
LASV spillover events per grid cell for (A) present day and (B) 2070 under a projected 876 
scenario of land use change, human population growth and climate change (RCP 6.5). Annual 877 
LASV spillover events are predicted using a spatially-explicit epidemiological model 878 
parameterized with M. natalensis distribution and human  population data, reported in [38]. 879 
(Figure reproduced from [38], © 2016 The Authors, under CC BY 4.0 license 880 
https://creativecommons.org/licenses/by/4.0/). 881 




